November 03, 2017 |
New York City, NY – November 3, 2017 – Patient advocacy and research organization COPD Foundation paid tribute to a special group of individuals and organizations at its Annual Awards Celebration in New York City on November 2, 2017. Held at the historic Metropolitan Club, the event’s honorees were recognized for their commitment to COPD awareness and the advancement of a COPD cure. Their advocacy, research, outreach, and care-delivery efforts have helped to build a broad understanding of the disease while improving lives of those directly affected. Gerard Turino, M.D., founding chairman of the COPD Foundation, received the highest honor for his achievements in COPD research and care delivery.
“Dr. Turino is known as an innovator and thought-leader in the field of COPD research,” says Craig Kephart, Chief Executive Officer of the COPD Foundation. “His work spans many decades, pioneering the way we look at the progression and treatment of COPD today. He has been at the forefront of this effort and has played an integral part in the formation and growth of the COPD Foundation.”
October 24, 2017 |
Jvion announced a collaboration with the COPD Foundation, Geisinger, GSK to improve the lives of chronic obstructive pulmonary disease (COPD) patients. The four organizations are teaming together to help individuals with COPD stay healthier, avoid hospitalizations, and prevent readmissions following an inpatient stay.
ATLANTA - October 24, 2017 - Jvion announced a unique collaboration with the COPD Foundation, Geisinger, and GSK aimed at improving the lives of chronic obstructive pulmonary disease (COPD) patients. Through an innovative approach that leverages cognitive machine technology and COPD patient data, the four organizations are teaming together in an effort to help individuals with COPD stay healthier, avoid hospitalizations, and prevent hospital readmissions following an inpatient stay. COPD encompasses a group of progressive lung diseases that gradually increase breathlessness and wheezing. The disease -- which includes emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis -- impacts more than 30 million people in the U.S. and is the nation’s third leading cause of death.
The goal of this ‘collaboratory’ project is to identify COPD patients at risk of hospitalization and most likely to benefit from new medications. The information is generated by Jvion’s Cognitive Clinical Success Machine, which identifies such patients currently under the care of Geisinger. The Cognitive Clinical Success Machine is an advanced artificial intelligence solution built using Eigenspace -- an approach that is a proven asset in solving complex challenges such as quantum mechanics, search and consumer behavior, facial recognition, and now patient deterioration. This Eigen-based solution enables a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
October 06, 2017 |
WASHINGTON, D.C. - October 6, 2017 - The COPD Foundation, a nonprofit organization dedicated to curing chronic obstructive pulmonary disease (COPD), has announced the details around its annual fundraiser. The COPD Annual Awards Celebration will be held November 2, 2017 at the Metropolitan Club in New York City from 6:30-9:30 p.m. The ceremony, hosted by COPD Foundation Board chairman Dr. Byron Thomashow, will pay tribute to individuals and organizations whose work has paved the way for COPD advocacy, research, and community building in 2017.
The Honorees are:
- John W. Walsh Visionary Award: Gerard M. Turino, M.D.
- Champion for COPD Award: Constance J. Milstein
- COPD Advocacy Award: Karen Deitemeyer
- COPD Awareness Award: FCB Health
September 29, 2017 |
WASHINGTON, D.C. – September 29, 2017 – The COPD Foundation announced today that Barbara Yawn, MD has joined the organization as Chief Scientific Officer. Dr. Yawn comes with 25 years of experience as a primary care researcher with a focus in respiratory disease, specifically asthma and chronic obstructive pulmonary disease (COPD). Additionally, she brings 14 years of full-time rural family medicine practice as well as training in research design and statistics. Dr. Yawn succeeds Dr. David Mannino in the role and will provide clinical oversight of the COPD Foundation’s overall research agenda going forward.
“Dr. Yawn is exceptionally well qualified to serve as the COPD Foundation’s chief scientific officer. She has been involved with the COPD Foundation since inception, including serving on the Foundation’s Medical and Scientific Advisory Committee (MASAC). As a primary care physician, Dr. Yawn has provided a unique and critical perspective,” says Craig Kephart, the COPD Foundation’s chief executive officer.
September 20, 2017 |
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single inhaler triple therapy comprising an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA) and long-acting beta agonist (LABA). Trelegy Ellipta is approved for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) who are receiving Breo and require additional bronchodilation or who are receiving Breo and Incruse.
September 19, 2017 |
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol. Trelegy Ellipta is not indicated for relief of acute bronchospasm or the treatment of asthma.
August 03, 2017 |
Washington, DC - August 3, 2017 - The COPD Foundation announced that four members of the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI) Division of Lung Disease, Airway Biology and Disease Branch were awarded the "2017 John W. Walsh Award for Advocacy on Behalf of COPD" at its COPD10usa conference in Chicago, IL on Saturday, July 26. This inaugural award was given on behalf of the COPD Conferences (UK and USA) that are committed to recognizing individuals who have made an outstanding contribution in the field of chronic obstructive pulmonary disease (COPD). Inductees are admitted to the COPD Hall of Fame.
June 29, 2017 |
WASHINGTON, D.C./CHICAGO - June 29, 2017 - The COPD Foundation will host COPD10usa, July 28-29 2017, at Hyatt Regency O’Hare, Chicago. The event will focus on chronic obstructive pulmonary disease (COPD), the nation's third leading cause of death, providing clinical and scientific knowledge for physicians, nurses, respiratory therapists and anyone involved with the management of individuals with COPD.
June 26, 2017 |
Washington, D.C. - June 26, 2017 - The COPD Foundation today announced the launch of the COPD and Pneumonia Study (CAP), a research initiative designed to describe the burden of pneumonia on individuals living with chronic obstructive pulmonary disease (COPD). COPD, a progressive lung disease characterized by wheezing and breathlessness, affects 30 million Americans. An acute lung infection, such as pneumonia, is potentially fatal for those living with COPD. The CAP study aims to provide the scientific community with evidence of pneumonia’s impact from the perspective of affected patients.
The CAP study is a multi-stakeholder project comprised of a series of online surveys. The project will expand upon past studies measuring the impact of pneumonia on the general population, but have not specifically observed high risk populations such as those living with COPD. It will address these limitations by utilizing a patient-reported outcomes instrument called CAP-Burden of Illness Questionnaire (CAP-BIQ) as the baseline and for the longitudinal components.
June 14, 2017 |
WASHINGTON, D.C. - June 14, 2017 - The COPD Foundation announced today a grant award from Insmed, Inc. to expand the Bronchiectasis and NTM Research Registry. The Registry is a consolidated database of non-cystic fibrosis Bronchiectasis (NCFB) and/or Nontuberculous Mycobacterium (NTM) patients from multiple clinical institutions across the United States. The goal of the Registry is to support collaborative research and assist in the planning of clinical trials for the treatment of non-CF Bronchiectasis and/or NTM lung disease. Expansion plans include enrollment of 1,200 new patients into the Registry and the addition of at least two new Consortium sites.
May 22, 2017 |
Washington, D.C. - May 22, 2017 - The National Institutes of Health in a collaborative effort with representatives from across the entire COPD community released the COPD National Action Plan. This first-of-its-kind document provides a unified framework to guide stakeholders nationwide in their efforts to work together to positively impact the effect of the disease
The COPD National Action Plan follows the COPD Town Hall held in 2016 where patients, caregivers, government representatives, and medical professionals convened to address the disparities in government funding of prevention, treatment, and research around chronic obstructive pulmonary disease (COPD). The COPD Foundation has long advocated for the need to create a comprehensive Action Plan to tackle the national epidemic. COPD is a lung disease characterized by an increasing inability to breathe and is the third leading cause of death in the U.S.
May 17, 2017 |
WASHINGTON, D.C. - May 17, 2017 - Regional air quality organization Clean Air Partners celebrated 20 years of dedication to improving the greater Baltimore-Washington region’s air quality at last night’s Annual Awards Celebration. Clean Air Partners has reinvigorated the celebration with the Best In Air Awards, honoring industry leaders COPD Foundation, Grid Alternatives, and Lyft for their exemplary commitment to decreasing air pollution and protecting public health. The Awards also recognized middle and high school students for their outstanding creativity as part of the On the Air education awards. The full list of Award winners can be found at www.cleanairpartners.net.
“This is a celebratory year for Clean Air Partners – you don’t turn 20 twice," says Jennifer Desimone of Clean Air Partners. “We wanted to take it up a notch and commend organizations and companies for their commitment to improving our region’s air quality and protecting the health of our residents. We nominated nearly 20 organizations and opened it up to public voting – we are honored to have the support from the incredible winners.”
The Most Valuable Partner (MVP) Award recognizes an organization that has made significant efforts to promote everyday actions to reduce air pollution and the impacts they have on climate change and public health. After a four week public voting period, the COPD Foundation secured the most votes in the MVP category.